Deferiprone for Acute Myocardial Infarction
This study is testing a drug called Deferiprone to see if it can reduce the amount of extra iron in the heart after a heart attack (acute myocardial infarction). Researchers believe Deferiprone might work by affecting a process called RAF. You might be able to join if you are 18-79 years old, have had a specific type of heart attack (anterior wall STEMI), and received a procedure called primary PCI. The study will look at how well Deferiprone works after 6 months. This study is currently unclear about its recruitment status and plans to enroll 89 participants.
- Study design
- This is a randomized, controlled pilot study where neither you nor your doctors will know if you are receiving Deferiprone or a placebo (an inactive pill). It plans to include 89 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess the treatment's effectiveness at 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
At a glance
Conditions
NCT05604131
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
IU Methodist Hospital (IUHealth)
Indianapolis, Indianano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Keyur P Vora, MD FACP FACC · PRINCIPAL_INVESTIGATOR · Medical Imaging Research Institute, Indiana University School of Medicine
- Rohan Dharmakumar, PhD · PRINCIPAL_INVESTIGATOR · Medical Imaging Research Institute, Indiana University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Treatment Efficacy6 months
Percentage reduction of hemorrhagic zone iron content by cardiac magnetic resonance at 6 months relative to baseline